Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Toyota Global Sales Fall as China Demand Slumps 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Add as a preferred source on Google
MINNEAPOLIS, April 06, 2018 -- Inspire Medical Systems, Inc. ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Inspire has applied to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.”
BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint lead book-running managers for the proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as co-managers for the proposed offering.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained from any of the following sources:
- BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: [email protected]; or
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].
A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Investor and Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]
646-597-6989
